Trials / Active Not Recruiting
Active Not RecruitingNCT06112743
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
MEMENTO - A Phase 4, Single-arm, Open-label Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy to Assess the Impact on Myocardial Structure With Cardiac Magnetic Resonance Imaging (CMR)
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) \[New York Heart Association (NYHA) Functional Class II or III\].
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mavacamten | Specified dose on specified days |
Timeline
- Start date
- 2024-01-24
- Primary completion
- 2026-07-09
- Completion
- 2026-07-09
- First posted
- 2023-11-01
- Last updated
- 2025-09-22
Locations
23 sites across 6 countries: United States, Argentina, Australia, Canada, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06112743. Inclusion in this directory is not an endorsement.